Ignite Creation Date:
2025-12-25 @ 2:02 AM
Ignite Modification Date:
2025-12-26 @ 12:26 AM
Study NCT ID:
NCT01467960
Status:
UNKNOWN
Last Update Posted:
2013-10-30
First Post:
2011-10-30
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Apolipoprotein D (ApoD) In Human Serum As Marker Of Parkinson's Disease
Sponsor:
Privatklinik Villa Melitta
Organization:
Study Overview
Official Title:
Detection of Apolipoprotein D (ApoD) in Human Serum as Marker of Parkinson's Disease
Status:
UNKNOWN
Status Verified Date:
2013-09
Last Known Status:
ENROLLING_BY_INVITATION
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ApoD
Brief Summary:
In Italy affected people are 200,000 and every year Parkinson new cases are 10,000. Aging is the principle risk factor of Parkinson with the possibility of its development doubling every five years after 65. Because of the increase of the social longevity and aging as the main risk factor, there are many repercussions on the health system (hospital stays and pharmaceutical costs) as on the social system (assistance- related problems). Parkinson's disease exerts an extremely negative impact on life's quality of the patient. In fact, because of Parkinson symptoms (tremor, dribble, etc), patient's social life will be reduced with the consequent development of the depression. Consequently, the early detection and treatment of Parkinson's is necessary.
To achieve this goal, Apolipoprotein D (ApoD) in human serum as a marker of the oxidative stress-inflammation vicious cycle seems most promising candidate for diagnosis.
To achieve this goal, Apolipoprotein D (ApoD) in human serum as a marker of the oxidative stress-inflammation vicious cycle seems most promising candidate for diagnosis.
Detailed Description:
Total participants: n=180.
Study Part 1:
Health persons: n=90; Groups of health persons: n=3; Subjects per group: n=30.
Study Part 2:
Patients: n=90; Groups of patients: n=3; Subjects per group: n=30.
Study Part 1:
Health persons: n=90; Groups of health persons: n=3; Subjects per group: n=30.
Study Part 2:
Patients: n=90; Groups of patients: n=3; Subjects per group: n=30.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: